Researchers reported that an mRNA‑delivered epigenetic editing therapy, dubbed Epi‑Reg, achieved long‑lasting reductions in PCSK9 expression and LDL cholesterol in human cells, mice and nonhuman primates, demonstrating durable and reversible effects after a single dose. The work, published in Nature Biotechnology, shows near‑year‑long cholesterol lowering in primates and positions epigenetic editing as a potentially safer, tunable alternative to permanent genome editing for cardiovascular risk reduction. The authors highlighted reversibility and a favorable safety profile in preclinical models.